Market by Product Type, Age Group, Distribution Channel, and Country Outlook | Forecast 2022-2028
Based on Triton’s report, the
Asia-Pacific cough syrup market is likely to progress with a CAGR of 3.69% during the forecast years
2022-2028.
Report scope can be customized per your requirements. Request For Customization
The
countries examined in the given region include:
•
China
•
Japan
•
India
•
South Korea
•
ASEAN Countries
•
Australia & New Zealand
•
Rest of Asia-Pacific
China
secures the major market share in the Asia-Pacific region. The region has witnessed a substantial rise in
respiratory diseases due to an increase in air pollution and growing smoking
culture. Moreover, greenhouse farming has emerged as a major issue, leading to
various respiratory diseases across numerous nations. The people in nations
like Japan, Thailand, and South Korea are highly vulnerable to the risk of
respiratory diseases, given the increase in the elderly population. Besides
this, household air pollution has increased the risk of tuberculosis, asthma,
and obstructive lung diseases. Thus, these factors majorly drive the cough
syrup market in the region.
In China, chronic obstructive pulmonary disease
is highly prevalent due to the rise in smoking and biomass fuels. Besides, this
disease has emerged as the fifth leading cause of death in the country. This
has caused an economic burden in rural and urban areas. Furthermore, the
country has around 320 million smokers, that account for almost 67% of the
total population base. This rise in smoking has surged the risk of lung
diseases. Along with this, greenhouse farming and the rise in air pollution are
other factors that augment the demand for cough syrups in the nation, fueling
the studied market’s growth.
Adult cough syrups comprise suppressants,
combination medicines, and expectorants. Over-the-counter adult cough syrups
are readily available; however, some require prescriptions. Several companies
like Novartis, Abbott, and Merck provide adult cough syrups. The cough syrup market’s growth is assessed
based on age group, distribution channel, and product type. The age cough
category is further segmented into adult and pediatric.
The
prominent companies thriving in the cough syrup market include Glenmark
Pharmaceuticals Limited, Acella Pharmaceuticals LLC, Johnson and Johnson,
GlaxoSmithKline, Dabur India Ltd, Cipla Limited, and Pfizer Inc.
Dabur India Ltd is a consumer goods company
engaged in manufacturing and marketing natural healthcare products. The company
offers numerous products, including fruit-based beverages, skincare products,
healthcare, and others. It offers products under brands such as Oxylife, FEM,
Gulabari, and others. Its product line includes Honitus cough syrup, an
ayurvedic medicine comprising medicinal plants recommended by Ayurveda in India.
Additionally, it markets products through e-commerce, retail chains,
pharmacies, and other channels. Dabur has operations across the globe, with
headquarters located in UP, India.
Key deliverables of the report:
●
Market CAGR during the forecasting years 2022-2028
●
Detailed data highlighting key insights, industry components, and
market strategies
● Comprehensive information and estimation of the cough syrup market
revenue growth in the Asia-Pacific and its influence on the parent market
●
In-depth study of forthcoming trends in consumer behavioral
patterns
●
A meticulous analysis of the competitive landscape, vendor
scorecard, and Porter’s Five Forces
● A wide-ranging study of factors that will challenge the APAC cough
syrup market’s growth during the upcoming years
Want to get specific insights? Our team of
analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Offerings, Technolog ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT1. ASIA-PACIFIC
COUGH SYRUP MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE COUGH SYRUP MARKET
2.2. KEY
INSIGHTS
2.2.1. INCREASING
DEMAND FOR HERBAL COUGH SYRUPS
2.2.2. COMPANIES
PROVIDE SUGAR-FREE COUGH SYRUPS
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. KEY
MARKET STRATEGIES
2.6.1. MERGERS
& ACQUISITIONS
2.6.2. DIVESTITURES
2.7. MARKET
DRIVERS
2.7.1. INCREASING
CHRONIC RESPIRATORY DISEASES
2.7.2. RISE
IN OLDER POPULATION
2.8. MARKET
CHALLENGES
2.8.1. OVERDOSE
RISK
2.8.2. STRICT
GOVERNMENT REGULATIONS AND RESTRICTIONS
2.9. MARKET
OPPORTUNITIES
2.9.1. INCREASE
IN CHILD-FRIENDLY COUGH SYRUP FLAVORS
2.9.2. GROWING
PREFERENCE FOR HOMEOPATHIC COUGH SYRUPS
2.9.3. SPECIAL
PEDIATRIC COUGH SYRUPS
3. ASIA-PACIFIC
COUGH SYRUP MARKET OUTLOOK - BY PRODUCT TYPE
3.1. COUGH
SUPPRESSANTS/ANTITUSSIVES
3.2. COMBINATION
MEDICATIONS
3.3. EXPECTORANTS
4. ASIA-PACIFIC
COUGH SYRUP MARKET OUTLOOK - BY AGE GROUP
4.1. ADULT
4.2. PEDIATRIC
5. ASIA-PACIFIC
COUGH SYRUP MARKET OUTLOOK - BY DISTRIBUTION CHANNEL
5.1. RETAIL
PHARMACY
5.2. HOSPITAL
PHARMACY
5.3. ONLINE
PHARMACY
6. ASIA-PACIFIC
COUGH SYRUP MARKET – COUNTRY OUTLOOK
6.1. CHINA
6.2. JAPAN
6.3. INDIA
6.4. SOUTH
KOREA
6.5. ASEAN
COUNTRIES
6.6. AUSTRALIA
& NEW ZEALAND
6.7. REST
OF ASIA-PACIFIC
7. COMPETITIVE
LANDSCAPE
7.1. ABBOTT
LABORATORIES
7.2. ACELLA
PHARMACEUTICALS LLC
7.3. ASTRAZENECA
PLC
7.4. CIPLA
LIMITED
7.5. DABUR
INDIA LTD
7.6. GLAXOSMITHKLINE
7.7. GLENMARK
PHARMACEUTICALS LIMITED
7.8. JOHNSON
AND JOHNSON
7.9. MERCK
KGAA
7.10. NOVARTIS
INTERNATIONAL AG
7.11. PFIZER
INC
7.12. PROCTOR
AND GAMBLE CO
7.13. RECKITT
BENCKISER GROUP PLC
7.14. SANOFI
SA
7.15. THE
HIMALAYA DRUG COMPANY
8. RESEARCH
METHODOLOGY & SCOPE
8.1. RESEARCH
SCOPE & DELIVERABLES
8.2. SOURCES
OF DATA
8.3. RESEARCH
METHODOLOGY
TABLE 1: ASIA-PACIFIC COUGH
SYRUP MARKET, BY COUNTRY, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: THE COUNTRIES WITH
THE LARGEST PERCENTAGE OF TOTAL POPULATION OVER 65 YEARS IN 2020
TABLE 4: ASIA-PACIFIC COUGH
SYRUP MARKET, BY PRODUCT TYPE, 2022-2028 (IN $ MILLION)
TABLE 5: ASIA-PACIFIC COUGH
SYRUP MARKET, BY AGE GROUP, 2022-2028 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC COUGH
SYRUP MARKET, BY DISTRIBUTION CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC COUGH
SYRUP MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE
1: MARKET ATTRACTIVENESS INDEX
FIGURE
2: ASIA-PACIFIC COUGH SYRUP MARKET, BY PRODUCT TYPE, 2021 & 2028 (IN %)
FIGURE
3: ASIA-PACIFIC COUGH SYRUP MARKET, BY COUGH SUPPRESSANTS/ANTITUSSIVES,
2022-2028 (IN $ MILLION)
FIGURE
4: ASIA-PACIFIC COUGH SYRUP MARKET, BY COMBINATION MEDICATIONS, 2022-2028 (IN $
MILLION)
FIGURE
5: ASIA-PACIFIC COUGH SYRUP MARKET, BY EXPECTORANTS, 2022-2028 (IN $ MILLION)
FIGURE
6: ASIA-PACIFIC COUGH SYRUP MARKET, BY AGE GROUP, 2021 & 2028 (IN %)
FIGURE
7: ASIA-PACIFIC COUGH SYRUP MARKET, BY ADULT, 2022-2028 (IN $ MILLION)
FIGURE
8: ASIA-PACIFIC COUGH SYRUP MARKET, BY PEDIATRIC, 2022-2028 (IN $ MILLION)
FIGURE
9: ASIA-PACIFIC COUGH SYRUP MARKET, BY DISTRIBUTION CHANNEL, 2021 & 2028
(IN %)
FIGURE
10: ASIA-PACIFIC COUGH SYRUP MARKET, BY RETAIL PHARMACY, 2022-2028 (IN $
MILLION)
FIGURE
11: ASIA-PACIFIC COUGH SYRUP MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $
MILLION)
FIGURE
12: ASIA-PACIFIC COUGH SYRUP MARKET, BY ONLINE PHARMACY, 2022-2028 (IN $
MILLION)
FIGURE
13: ASIA-PACIFIC COUGH SYRUP MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE
14: CHINA COUGH SYRUP MARKET 2022-2028 (IN $ MILLION)
FIGURE
15: JAPAN COUGH SYRUP MARKET 2022-2028 (IN $ MILLION)
FIGURE
16: INDIA COUGH SYRUP MARKET 2022-2028 (IN $ MILLION)
FIGURE
17: SOUTH KOREA COUGH SYRUP MARKET 2022-2028 (IN $ MILLION)
FIGURE
18: ASEAN COUNTRIES COUGH SYRUP MARKET 2022-2028 (IN $ MILLION)
FIGURE
19: AUSTRALIA & NEW ZEALAND COUGH SYRUP MARKET 2022-2028 (IN $ MILLION)
FIGURE
20: REST OF ASIA-PACIFIC COUGH SYRUP MARKET 2022-2028 (IN $ MILLION)